|Awarded On||February 16, 2022|
|Title||A randomized, controlled trial comparing the immunogenicity of 2 doses vs 3 doses of the 9-valent HPV vaccine in females 27-45 years of age|
|Award Mechanism||Individual Investigator Research Awards for Prevention and Early Detection|
|Institution/Organization||The University of Texas Medical Branch at Galveston|
|Principal Investigator/Program Director||Abbey Berenson|
|Cancer Sites||Cervix Uteri|
HPV is associated with cancer of the cervix, vulva, vagina, anus, oropharynx, and penis. Fortunately, a vaccine is available which has the potential to markedly reduce, or even eliminate, these cancers. The CDC recommends that it be administered at age 11-12 years although it may be given as young as 9. For those not vaccinated at a younger age, it was originally recommended up to age 26. This was recently extended to age 45. The CDC estimates that 80% of those eligible need to be completely vaccinated to reach herd immunity. However, this goal remains out-of-reach as vaccine completion rates are extremely low in the US, especially among adults. One reason for this is that multiple doses are...